Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Journal of Alzheimer'S Disease : JAD|January 10, 2022
Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature ReviewRuth Benca, W Joseph Herring, Rezaul Khandker, et al.
Journal of Sleep Research|October 20, 2018
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indicationsW Joseph Herring, Thomas Roth, Andrew D Krystal, et al.
Journal of Sleep Research|November 19, 2020
Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severityEllen S Snyder, Peining Tao, Vladimir Svetnik, et al.
Sleep|September 9, 2014
Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjectsJunshui Ma, Vladimir Svetnik, Ellen Snyder, et al.
Sleep Medicine|December 18, 2022
Comparison of polysomnography in people with Alzheimer's disease and insomnia versus non-demented elderly people with insomniaPeining Tao, Vladimir Svetnik, Donald L Bliwise, et al.
Sleep Medicine|January 12, 2020
How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?Vladimir Svetnik, Ellen S Snyder, Peining Tao, et al.
Clinical and Translational Science|December 5, 2020
Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing SurgeryKate Mostoller, Rebecca Wrishko, Lata Maganti, et al.
The Clinical Journal of Pain|April 28, 2017
Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With FilorexantW Joseph Herring, Joy Y Ge, Saheeda Jackson, et al.
Annual Review of Pharmacology and Toxicology|November 19, 2016
The Discovery of Suvorexant, the First Orexin Receptor Drug for InsomniaPaul J Coleman, Anthony L Gotter, W Joseph Herring, et al.
BMC Anesthesiology|February 28, 2021
Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trialJay C Horrow, Wen Li, Manfred Blobner, et al.
Pageof 4